Guangzhou Innogen Pharmaceutical Group (HKG:2591) raised HK$634.7 million in net proceeds from its initial public offering in Hong Kong, according to a Thursday after-market Hong Kong bourse filing.
The pharmaceutical firm priced its 36,556,400 H-shares at HK$18.68 apiece.
The Hong Kong public offer was 5,341.66 times oversubscribed, with the final allocation of 3,655,800 shares, or about 10% of the total offering, unchanged from the initial allotment.
The international offering was 10.67 times subscribed, with the final number of shares offered remaining at 32,900,600.
Cornerstone investors June Star Global, Ginkgo Capital Global Fund - SPC XtalPi AI Fund SP, Marketingforce Management, Deng Haifeng, and Li Huifeng were allotted a combined 4,201,000 shares, or about 11.49% of the global offering.
Guangzhou Innogen Pharma is set to debut on the Hong Kong bourse on Friday, Aug. 15.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.